DnaJ heat shock protein family (Hsp40) member C13Genealiases: PARK21 · RME8
Q-omics provides the consensus-scored DNAJC13 profile across patient tissues and cancer cell-line models. DNAJC13 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DNAJC13 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DNAJC13 protein abundance shows 32,945 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where DNAJC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC13 survival associations across molecular data types. DNAJC13 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC13 RNA expression–survival associations across cancer types. High DNAJC13 expression shows unfavorable associations in UVM, KICH and LUSC, but favorable associations in KIRC, UCS and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DNAJC13 RNA expression.
This table summarizes DNAJC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC13 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, KIRP and KIRC. The HNSC box plot shows higher DNAJC13 RNA expression in tumor versus normal tissue (log2 FC = +0.849, t-test p < 0.001).
This table shows molecular features associated with DNAJC13 in patient tissues and cancer cell lines. In patient samples, DNAJC13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
